Funding Opportunity RFA-DA-21-015 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research applications for commercializable products aimed at reducing stigma around substance use disorders (SUD). Phase I applications are invited to develop and evaluate feasibility of novel digital technologies, services or other interventions to reduce stigma towards SUD in clinical care, including HIV prevention and care settings, clinical training and other relevant settings, and to establish methods to measure stigma reduction. Phase II applications are invited to demonstrate efficacy in decreasing stigma towards SUD and commercialization potential of these products in clinical care, training, and/or other relevant settings, including those providing HIV prevention and care with the goal to remove barriers to SUD prevention, treatment, and support during recovery. Phase II applications focused on HIV prevention and care settings are invited to demonstrate efficacy in decreasing stigma towards SUD and improving health outcomes for people living with HIV and SUD.

Notice NOT-MD-21-009 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Head of Human Resources, EMBL-EBI Location: Cambridge, Cambridgeshire, England

Funding Opportunity PAR-21-100 from the NIH Guide for Grants and Contracts. This FOA is intended to: (1) increase our understanding of how music affects the brain when it is used therapeutically and/or (2) use that knowledge to better develop evidence-based music interventions to enhance health or treat specific diseases and disorders. Proposed R01 projects can investigate how music is processed by or modifies the brain, or how it affects specific biological functions during childhood development and learning, adulthood, and aging. Projects can also include preliminary interventions that provide a basis for therapeutic interventions. When appropriate, collaborations among basic researchers, technology developers, music intervention experts, or other clinical researchers are highly encouraged.

Funding Opportunity PAR-21-099 from the NIH Guide for Grants and Contracts. This FOA is intended to: (1) increase our understanding of how music affects the brain when it is used therapeutically and/or (2) use that knowledge to better develop evidence-based music interventions to enhance health or treat specific diseases and disorders.

Candidates should have experience working with common computer applications used in lab operations and data analysis (Word, PowerPoint, Excel, etc.).
From University of Wisconsin–Madison - Wed, 23 Dec 2020 00:57:51 GMT - View all Madison, WI jobs

Up to £45,000 plus full benefits package: Singular Talent: NGS expert with a drive to contribute to truly novel drug research? Read on..... Oxford, Oxfordshire (GB)

Funding Opportunity RFA-DA-21-032 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research applications for commercializable, digital health-based products that aim at positively affecting the fundamental social and environmental conditions that are risk factors for the populations affected by the use of drugs, including opioids.

Funding Opportunity RFA-DA-21-031 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research applications for commercializable, digital health-based products that aim at positively affecting the fundamental social and environmental conditions that are risk factors for the populations affected by the use of drugs, including opioids.

Notice NOT-OD-21-042 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Bioinformatician (Open Targets) Location: Cambridge, Cambridgeshire, England

Notice NOT-MH-21-140 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-136 from the NIH Guide for Grants and Contracts

Notice NOT-HD-20-046 from the NIH Guide for Grants and Contracts

Notice NOT-HD-20-045 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-092 from the NIH Guide for Grants and Contracts. The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.

Notice NOT-CA-21-026 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-020 from the NIH Guide for Grants and Contracts

Notice NOT-EY-21-007 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-004 from the NIH Guide for Grants and Contracts